Checkmate Pharmaceuticals Inc. (CMPI) News
Filter CMPI News Items
CMPI News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
CMPI News Highlights
- CMPI's 30 day story count now stands at 6.
- Over the past 21 days, the trend for CMPI's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
- DRUG, AIM and ALX are the most mentioned tickers in articles about CMPI.
Latest CMPI News From Around the Web
Below are the latest news stories about Checkmate Pharmaceuticals Inc that investors may wish to consider to help them evaluate CMPI as an investment opportunity.
Toll-Like Receptor Agonist Pipeline Insights | Research Report 2022 by DelveInsightLas Vegas, USA, Feb. 21, 2022 (GLOBE NEWSWIRE) -- Toll-Like Receptor Agonist Pipeline Insights | Research Report 2022 by DelveInsight Toll-Like Receptor Agonist Pipeline constitutes 45+ key companies continuously working towards developing 45+ Toll-Like Receptor Agonist treatment therapies, analyzes DelveInsight DelveInsight''s Toll-Like Receptor Agonist Pipeline Insight 2022'' report offers exhaustive global coverage of available, marketed, and pipeline therapies in different phases of clinical development, major pharmaceutical companies working to advance the pipeline space, and future growth potential of the Toll-Like Receptor Agonist pipeline domain. Some of the essential takeaways from the Toll-Like Receptor Agonist Pipeline report: DelveInsight''s Toll-Like Receptor (TLR) Agonist... |
The Petri Dish: Syndax, Checkmate get new CEOs; Biogen stays in biosimilars gameWhile some in the life sciences industry create drugs and devices to tackle the Covid-19 pandemic, their colleagues are busy as ever raising money, testing new drugs, expanding facilities and more. |
Checkmate Pharmaceuticals appoints Alan Bash as President, CEOCheckmate Pharmaceuticals (CMPI) announced the appointment of Alan Bash as President and Chief Executive Officer, effective March 1, 2022 |
Checkmate Pharmaceuticals Appoints Alan Bash as President and CEOAccomplished global biopharmaceutical executive with over 20 years of strategic and operational leadership at Bristol Myers SquibbCAMBRIDGE, Mass., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (Nasdaq: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced the appointment of Alan Bash as President and Chief Executive Officer, effective March 1 |
Checkmate Pharmaceuticals Welcomes Industry Leader Jon Wigginton, M.D. to its Board of DirectorsCAMBRIDGE, Mass., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced the addition of Jon Wigginton, M.D. to its Board of Directors (“Board”). “Jon is a well-respected physician-scientist and drug development expert. With his diverse background, he has driven numerous clinical stage immu |
One Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI) insider upped their stake by 2.5% in the previous yearViewing insider transactions for Checkmate Pharmaceuticals, Inc.'s ( NASDAQ:CMPI ) over the last year, we see that... |
Checkmate Pharmaceuticals to Present at the H.C. Wainwright BioConnect Virtual ConferenceCAMBRIDGE, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced that Alan Fuhrman, Interim CEO and President, will present at the H.C. Wainwright BioConnect Virtual Conference being held on January 10-13, 2022. The pre-recorded webcast will be available on-demand starting on Monday |
Checkmate Pharmaceuticals Announces Initiation of Patient Dosing in Phase 2 Multi-Indication Trial Using VidutolimodCAMBRIDGE, Mass., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced that patient dosing was initiated in the anti-PD-1 refractory cutaneous squamous cell carcinoma (CSCC) arm of a Phase 2 multi-indication study evaluating the efficacy and safety of vidutolimod in combination with cemip |
Checkmate Pharmaceuticals Strengthens Board of Directors with Appointment of Joy Yan, M.D., Ph.D.Nilesh Kumar, Ph.D. departs Board of Directors upon transition to new role at Wellington ManagementCAMBRIDGE, Mass., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced the addition of Joy Yan, M.D., Ph.D. to its Board of Directors (“Board”). “Joy’s impressive track record in immuno-onco |
Zacks: Brokerages Anticipate Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI) to Post -$0.74 EPSBrokerages forecast that Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI) will report ($0.74) earnings per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Checkmate Pharmaceuticals earnings, with estimates ranging from ($0.74) to ($0.73). The business is expected to report its next earnings report on Monday, April 4th. According to Zacks, analysts [] |